Dr Conlin on Targeting CNS Metastases in the Treatment of Breast Cancer
Alison K. Conlin, MD, discusses the importance of targeting central nervous system metastases in the treatment of patients with breast cancer, highlighting ongoing treatment investigations for this population.
Dr Conlin on CDK4/6 Inhibitor Sequencing and QOL in Breast Cancer
Alison K. Conlin, MD, discusses unanswered questions regarding the use of CDK4/6 inhibitors after prior progression on CDK4/6 inhibitors and quality of life considerations in patients with breast cancer.
Dr. Conlin on the Implications of the HER2-Low Subset in Breast Cancer
Alison K. Conlin, MD, discusses the inception of the HER2-low breast cancer treatment landscape.
Dr. Conlin on theBenefits of Trastuzumab Deruxtecan in HER2-Low Breast Cancer
Alison K. Conlin, MD, discusses the benefits of trastuzumab deruxtecan in HER2-low breast cancer.
Dr. Conlin on the Practice-Changing Data of Trastuzumab Deruxtecan in HER2+ Breast Cancer
Alison K. Conlin, MD, discusses the practice-changing data of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.
MRD Positivity Correlates With Allogeneic Transplant Benefits in NPM1-Mutated AML
Orca-T Shows High Survival Rates in Intermediate-/High-Risk Myelodysplastic Syndrome
Orca-T Demonstrates Feasibility in Older Patients With Hematologic Malignancies
Second-Line Axi-Cel Prolongs Survival Over SOC in Elderly Patients With R/R LBCL
2 Clarke Drive Cranbury, NJ 08512